Researchers at the University of Minnesota have identified microRNAs that may cause colon polyps from turning cancerous. The finding could help physicians provide more specialized, and earlier, treatment before colon cancer develops. The findings are published today in The Journal of Pathology.
The American Cancer Society estimates over 134,000 people will be diagnosed with colon cancer in 2014, despite the expanded screening processes now available. This year alone, about 50,000 people will die because of the disease.
Research was led by Subbaya Subramanian, Ph.D., assistant professor in the Division of Basic and Translational Research in the Department of Surgery in the University of Minnesota Medical School and member of the Masonic Cancer Center, University of Minnesota.
"With the advanced screenings we now have available, why are so many people still being diagnosed with colon cancer? We really wanted to understand if there was a way to stop the disease before it starts, before benign polyps became cancerous tumors," said Subramanian.
By looking at microRNA, Subramanian and his colleagues hoped to unlock what pieces were present in colon polyps that developed into cancer. They found miR-182 and miR-503 work together to transform a benign polyp to a cancerous tumor by holding down the cell's ability to create the tumor suppressing protein FBXW7.
This was determined by looking at a benign polyp cell line. In this line, miR-182 was present and appeared as a feature of the creation of adenomas, or polyps. Researchers then introduced miR-503 to the cell line and noted the partnership limited the tumor suppressing protein and polyps had a much higher potential for becoming cancerous.
Armed with this knowledge, the researchers then took a closer look at actual patient data. They examined the expression of miR-182 and miR-503 in colon cancer patients with a 12-year survival outcome data. When both microRNAs were present at higher levels, decreased patient survival was clearly correlated.
"It suggests a biomarker for colon cancer patients, something ideally physicians can one day screen for as a diagnostic and prognostic tool," said Subramanian.
Subramanian believes the next step will be determining if drugs are able to target miR-182 and -503, as well was what miR-182 and -503 do after suppressing FBXW7. He hopes to develop a clinical test as well as a translational target for treatments to be utilized in a clinical setting.
This study was supported by the Department of Surgery, University of Minnesota Medical School. Patient sets were utilized in partnership with the Mayo Clinic, Rochester, MN.
The University of Minnesota Medical School, with its two campuses in the Twin Cities and Duluth, is a leading educator of the next generation of physicians. Our graduates and the school's 3,800 faculty physicians and scientists advance patient care, discover biomedical research breakthroughs with more than $180 million in sponsored research annually, and enhance health through world-class patient care for the state of Minnesota and beyond. Visit http://www.med.umn.edu to learn more.
Masonic Cancer Center, University of Minnesota is part of the University's Academic Health Center. It is designated by the National Cancer Institute as a Comprehensive Cancer Center. For more information about the Masonic Cancer Center, visit http://www.cancer.umn.edu or call 612-624-2620.
Caroline Marin | Eurek Alert!
New application for acoustics helps estimate marine life populations
16.01.2018 | University of California - San Diego
Unexpected environmental source of methane discovered
16.01.2018 | University of Washington Health Sciences/UW Medicine
08.01.2018 | Event News
11.12.2017 | Event News
08.12.2017 | Event News
17.01.2018 | Ecology, The Environment and Conservation
17.01.2018 | Physics and Astronomy
17.01.2018 | Awards Funding